Summary
Seventy-five children with recurrent, progressive or metastatic primary brain tumors were treated with aziridinylbenzoquinone (AZQ; Diaziquone) at 9 mg/m2/day by 30-minute intravenous infusion for five days every three weeks. Sixty-six patients were evaluable for response by imaging studies. There were five partial responses and one complete response for a combined response rate of 9%. A complete response lasting for 35 + months occurred in one of twelve patients with metastatic or locally recurrent ependymoma. Objective responses were also seen in patients with primitive neuroectodermal tumors (PNET) (1/8), low-grade glioma (1/6), and primary central nervous system lymphoma (1/1). Stable disease of greater than six months duration was seen in patients with ependymoma, PNET and medulloblastoma. Profound and prolonged myelosuppression was the significant toxicity observed. As administered in this study, AZQ has marginal activity and severe toxicity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bender JF, Grillo-Lopez AJ, Posada Jr JG: Diaziquone (AZQ). Invest New Drugs 1: 71–84, 1983
Falletta J, Kamen B, Ragab A, Starling K, Diaziquone by prolonged infusion (Abstr). Proc Amer Assoc Canc Res 25: 201, 1984
Schold Jr SC, Friedman HS, Bjornsson TD, Falletta JM: Treatment of patients with recurrent primary brain tumors with AZQ. Neurology 34: 615–619, 1984
Fenn LG, Yung WKA, Leavens ME, Burgess MA, Obbens EA, Bedikian AY, Savaraj N, Stewart DJ, Benjamin RS, Fields WS, Bodey GP: A phase II trial of 2,5,-diaziridinyl 3,6-bis (carboethoxy amino) 1,4-benzoquinone (AZQ, NSC 182986) in recurrent primary brain tumors. J Neuro-Oncol 2: 13–17, 1984
Curt GA, Kelley JA, Kufta CV, Smith BH, Kornblith PL, Young RC, Collins JM: Phase II and pharmacokinetic study of aziridinylbenzoquinone (2,5-Diaziridinyl-3,6,bis (carboethoxyamino)-1,4-benzoquinone, Diaziquone, NSC 182986) in high-grade gliomas. Cancer Res 43: 6102–6105, 1983
Maral J, Poisson M, Pertuiset BF, Mashaly P, Weil M, Jacquillat Cl, Grillo-Lopez AJ: Phase II evaluation of diaziquone (CI-904, AZQ) in the treatment of human malignant glioma. J Neuro-Oncol 3: 245–249, 1985
Eagan RT, Dinapoli RP, Cascino TL, Scheithauer B, O'Neill BP, O'Fallon JR: Comprehensive phase II evaluation of aziridinylbenzoquinone (AZQ, Diaziquone) in recurrent human brain tumors. J Neuro-Oncol 5: 309–314, 1987
Haid M, Khandekar JD, Christ M, Johnson CM, Miller SJ, Locker GY, Merrill JM, Reisel H, Hatfield A, Lanzotti V, Stiff P, Shaw J, Krauss S, Showel J, Blough R, Gordon L: Aziridinylbenzoquinone in recurrent, progressive glioma of the central nervous system. A phase II study by the Illinois Cancer Council. Cancer 56: 1311–1315, 1985
Decker DA, Al Sarraf M, Kresge C, Austin D, Wilner HI: Phase II study of aziridinylbenzoquinone (AZQ: NSC-182986) in the treatment of malignant gliomas recurrent after radiation. J Neuro-Oncol 3: 19–21, 1985
Aroney RS, Kaplan RS, Salcman M, Montgomery E, Wiernik PH: A phase II trial of AZQ (NSC 182986) in patients with recurrent primary or metastatic brain tumors (Abstr). Proc Amer Soc Clin Oncol 1: 24, 1982
Ettinger LJ, Siegel SE, Belasco JB, Evans AE, Ruccione KS, Jamin DC, Rohrbaugh TM, Higgins GR: Phase I clinical evaluation of diaziquone in childhood cancer. Cancer Treat Rep 69: 323–327, 1985
Tan CTC, Hancock CH, Mondora A, Hoffman NW: Phase I study of aziridinylbenzoquinone (AZQ, NSC 182986) in children with cancer. Cancer Res 44: 831–835, 1984.
Author information
Authors and Affiliations
Additional information
Contributing Childrens Cancer Study Group Investigators, Institutions, and Grant Numbers are given in the Appendix. Grant support from the Division of Cancer Treatment, National Cancer Institute, National Institutes of Health, Department of Health and Human Services.
Rights and permissions
About this article
Cite this article
Ettinger, L.J., Ru, N., Krailo, M. et al. A phase II study of diaziquone in children with recurrent or progressive primary brain tumors: A report from the Childrens Cancer Study Group. J Neuro-Oncol 9, 69–76 (1990). https://doi.org/10.1007/BF00167071
Issue Date:
DOI: https://doi.org/10.1007/BF00167071